(AOF) – Clariane has announced capital increase operations intended to strengthen its financial structure for a maximum total amount of approximately 328 million euros. This operation is part of a plan announced by the group last November intended to reduce debt and strengthen its financial structure, while the group is facing significant financing difficulties. The company has also announced that it will welcome the HLD Europe group as a new reference shareholder.
HLD Europe will subscribe for a 20% stake in the capital as part of a reserved capital increase, which will be submitted to a vote at the next shareholders’ meeting on June 10, Clariane said.
HLD Europe would subscribe 74.1 million euros of the capital increase, specifies a press release from Clariane.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.